Loading…
Update on the treatment of type 2 diabetes mellitus
To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different...
Saved in:
Published in: | World journal of diabetes 2016-09, Vol.7 (17), p.354-395 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3 |
---|---|
cites | |
container_end_page | 395 |
container_issue | 17 |
container_start_page | 354 |
container_title | World journal of diabetes |
container_volume | 7 |
creator | Juan Jose Marin-Penalver Iciar Martin-Timon Cristina Sevillano-Collantes Francisco Javier del Canizo-Gomez |
description | To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade. |
doi_str_mv | 10.4239/wjd.v7.i17.354 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5027002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>7000168841</cqvip_id><sourcerecordid>1823037043</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3</originalsourceid><addsrcrecordid>eNpVkN1LwzAUxYMobsy9-igFX3xpzWeTvggy_IKBL-45pO3t1tE2XZNN9t8b2RwzcMmF-8u5JwehW4ITTln2-L0uk51MaiITJvgFGpOMqzhjQl2e9SM0dW6Nw-EiTVl2jUZUpilOMzFGbNGXxkNku8ivIPIDGN9C5yNbRX7fQ0SjsjY5eHBRC01T-627QVeVaRxMj_cELV5fvmbv8fzz7WP2PI8LxpWPlRI5wYJQUggVimJQQEGEzQWlRAoKucmlUYGSOaVYVSINpCkwhyoHNkFPB91-m7dQFsHWYBrdD3Vrhr22ptb_J1290ku70wJTiTENAg9HgcFutuC8bmtXhF-YDuzWaaIow0xizgKaHNBisM4NUJ3WEKx_w9YhbL2TOoStQ9jhwd25uRP-F20A7o-KK9stN3W3PDHBHCapUpywH2mrhm4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1823037043</pqid></control><display><type>article</type><title>Update on the treatment of type 2 diabetes mellitus</title><source>PMC (PubMed Central)</source><creator>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creator><creatorcontrib>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creatorcontrib><description>To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.</description><identifier>ISSN: 1948-9358</identifier><identifier>EISSN: 1948-9358</identifier><identifier>DOI: 10.4239/wjd.v7.i17.354</identifier><identifier>PMID: 27660695</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>agents ; antidiabetic ; diabetes ; Future ; impairment ; Injectable ; mellitus ; Older ; Oral ; people ; Renal ; Review ; Treatment ; treatments ; Type</subject><ispartof>World journal of diabetes, 2016-09, Vol.7 (17), p.354-395</ispartof><rights>The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/71418X/71418X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027002/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027002/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27660695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creatorcontrib><title>Update on the treatment of type 2 diabetes mellitus</title><title>World journal of diabetes</title><addtitle>World Journal of Diabetes</addtitle><description>To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.</description><subject>agents</subject><subject>antidiabetic</subject><subject>diabetes</subject><subject>Future</subject><subject>impairment</subject><subject>Injectable</subject><subject>mellitus</subject><subject>Older</subject><subject>Oral</subject><subject>people</subject><subject>Renal</subject><subject>Review</subject><subject>Treatment</subject><subject>treatments</subject><subject>Type</subject><issn>1948-9358</issn><issn>1948-9358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkN1LwzAUxYMobsy9-igFX3xpzWeTvggy_IKBL-45pO3t1tE2XZNN9t8b2RwzcMmF-8u5JwehW4ITTln2-L0uk51MaiITJvgFGpOMqzhjQl2e9SM0dW6Nw-EiTVl2jUZUpilOMzFGbNGXxkNku8ivIPIDGN9C5yNbRX7fQ0SjsjY5eHBRC01T-627QVeVaRxMj_cELV5fvmbv8fzz7WP2PI8LxpWPlRI5wYJQUggVimJQQEGEzQWlRAoKucmlUYGSOaVYVSINpCkwhyoHNkFPB91-m7dQFsHWYBrdD3Vrhr22ptb_J1290ku70wJTiTENAg9HgcFutuC8bmtXhF-YDuzWaaIow0xizgKaHNBisM4NUJ3WEKx_w9YhbL2TOoStQ9jhwd25uRP-F20A7o-KK9stN3W3PDHBHCapUpywH2mrhm4</recordid><startdate>20160915</startdate><enddate>20160915</enddate><creator>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creator><general>Baishideng Publishing Group Inc</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160915</creationdate><title>Update on the treatment of type 2 diabetes mellitus</title><author>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>agents</topic><topic>antidiabetic</topic><topic>diabetes</topic><topic>Future</topic><topic>impairment</topic><topic>Injectable</topic><topic>mellitus</topic><topic>Older</topic><topic>Oral</topic><topic>people</topic><topic>Renal</topic><topic>Review</topic><topic>Treatment</topic><topic>treatments</topic><topic>Type</topic><toplevel>online_resources</toplevel><creatorcontrib>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</creatorcontrib><collection>维普_期刊</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Juan Jose Marin-Penalver;Iciar Martin-Timon;Cristina Sevillano-Collantes;Francisco Javier del Canizo-Gomez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Update on the treatment of type 2 diabetes mellitus</atitle><jtitle>World journal of diabetes</jtitle><addtitle>World Journal of Diabetes</addtitle><date>2016-09-15</date><risdate>2016</risdate><volume>7</volume><issue>17</issue><spage>354</spage><epage>395</epage><pages>354-395</pages><issn>1948-9358</issn><eissn>1948-9358</eissn><abstract>To achieve good metabolic control in diabetes and keep long term, a combination of changes in lifestyle and pharmacological treatment is necessary. Achieving nearnormal glycated hemoglobin significantly, decreases risk of macrovascular and microvascular complications. At present there are different treatments, both oral and injectable, available for the treatment of type 2 diabetes mellitus (T2DM). Treatment algorithms designed to reduce the development or progression of the complications of diabetes emphasizes the need for good glycaemic control. The aim of this review is to perform an update on the benefits and limitations of different drugs, both current and future, for the treatment of T2DM. Initial intervention should focus on lifesty lechanges. Moreover, changes in lifestyle have proven to be beneficial, but for many patients is a complication keep long term. Physicians should be familiar with the different types of existing drugs for the treatment of diabetes and select the most effective, safe and better tolerated by patients. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on thecharacteristics of each patient. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>27660695</pmid><doi>10.4239/wjd.v7.i17.354</doi><tpages>42</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1948-9358 |
ispartof | World journal of diabetes, 2016-09, Vol.7 (17), p.354-395 |
issn | 1948-9358 1948-9358 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5027002 |
source | PMC (PubMed Central) |
subjects | agents antidiabetic diabetes Future impairment Injectable mellitus Older Oral people Renal Review Treatment treatments Type |
title | Update on the treatment of type 2 diabetes mellitus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A33%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Update%20on%20the%20treatment%20of%20type%202%20diabetes%20mellitus&rft.jtitle=World%20journal%20of%20diabetes&rft.au=Juan%20Jose%20Marin-Penalver;Iciar%20Martin-Timon;Cristina%20Sevillano-Collantes;Francisco%20Javier%20del%20Canizo-Gomez&rft.date=2016-09-15&rft.volume=7&rft.issue=17&rft.spage=354&rft.epage=395&rft.pages=354-395&rft.issn=1948-9358&rft.eissn=1948-9358&rft_id=info:doi/10.4239/wjd.v7.i17.354&rft_dat=%3Cproquest_pubme%3E1823037043%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c348t-885b105121c581c520e8e2e5606c221752ebab7a8b107b2208f56581ac04efbe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1823037043&rft_id=info:pmid/27660695&rft_cqvip_id=7000168841&rfr_iscdi=true |